REPLIGEN DROPS HIV VACCINE PROGRAM AS PART OF STREAMLINING
Executive Summary
REPLIGEN DROPS HIV VACCINE PROGRAM AS PART OF STREAMLINING announced July 19. Repligen's RP400c therapeutic HIV vaccine targeting the V3 loop of the virus was in Phase I studies at the University of Colorado, and the company was also involved in research for a prophylactic vaccine. Both programs have been dropped because of "a lack of available funding and the exponentially increasing expenses associated with the clinical development of an HIV vaccine," Repligen said.